Blue Dye 2 vs Monosodium Glutamate: which is worse?

What is Blue Dye 2?

Blue Dye 2 (Indigotine/Indigo Carmine) is a synthetic disulfonated derivative of indigo. Unlike natural indigo from the indigo plant, the FD&C version is synthetically manufactured from petroleum. It produces a dark royal blue to indigo color and is used in food, pharmaceuticals, and medical diagnostics.

What is Monosodium Glutamate?

Monosodium glutamate (MSG) is the sodium salt of glutamic acid, a naturally occurring non-essential amino acid found in many proteins. It is used as a flavor enhancer to intensify umami (savory) taste. MSG was first isolated from seaweed in 1908 by Japanese chemist Kikunae Ikeda and has been used commercially since then.

Documented risks

Blue Dye 2: Animal studies conducted in the 1980s found that high-dose Blue Dye 2 caused brain tumors in male rats. An NTP bioassay (1987) found statistically significant increases in brain gliomas (astrocytomas) in male rats given high doses. The FDA reviewed these findings and determined that the doses far exceeded typical human dietary exposure. Nonetheless, the tumor finding remains in the scientific record as a concerning data point. EFSA's 2010 safety evaluation of Indigo Carmine (E132) reached an unusual conclusion: it could not establish an ADI due to data limitations, including the brain tumor findings. This means EFSA adopted an implicit conservative position — it neither declared Blue 2 safe nor formally banned it, but the absence of an established ADI signals scientific uncertainty. In medical diagnostic use, high intravenous doses of Indigo Carmine can cause hypertension, bradycardia, and in rare cases anaphylaxis. These are dose-specific clinical pharmacological effects, not relevant to dietary consumption at food use levels. Blue 2 was not included in the 2007 Lancet hyperactivity study. Limited direct research links Blue 2 to behavioral effects. The FDA's April 2025 announcement includes Blue 2 in the class of petroleum-based synthetic dyes to be phased out of the US food supply, reflecting updated policy on the category rather than specific new Blue 2 toxicity data.

Monosodium Glutamate: MSG safety has been one of the most extensively debated food additive questions in the past 50 years. The 'Chinese Restaurant Syndrome' — a cluster of symptoms (headache, flushing, sweating, chest tightness) reported after eating Chinese food — was attributed to MSG in a 1968 letter in the New England Journal of Medicine. This set off decades of controversy. Multiple rigorous double-blind, placebo-controlled trials have failed to consistently demonstrate that MSG at doses present in food causes these symptoms when participants do not know whether they received MSG or a placebo. A comprehensive 1993 review by the FDA-commissioned Federation of American Societies for Experimental Biology (FASEB) found that while some sensitive individuals may experience symptoms at high doses (>3g of pure MSG on an empty stomach), the doses in typical food servings do not consistently produce symptoms in double-blind conditions. The FDA classifies MSG as GRAS (generally recognized as safe). EFSA's 2017 re-evaluation set an ADI of 30 mg/kg body weight per day, acknowledging that very high doses could affect neurological function but concluding typical dietary exposure is safe. Critics including Dr. Russell Blaylock and advocacy groups have argued that MSG is an 'excitotoxin' — a compound that overstimulates glutamate receptors in the brain and could cause neuronal damage. While glutamate is indeed a neurotransmitter and high-dose glutamate can cause neurotoxicity in animal models, the blood-brain barrier and normal metabolic regulation are generally considered sufficient to prevent dietary MSG from affecting brain glutamate levels. A 2018 EFSA re-evaluation noted that combined exposure to glutamates from all sources (including naturally occurring glutamate in protein-rich foods and other added glutamates E621-E625) could approach the new lower ADI in high consumers — a concern particularly for children with high processed food intake.